NASDAQ:DCPH

China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor

SHANGHAI and SAN FRANCISCO and WALTHAM, Mass., July 20, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB) and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ripretinib...

2020-07-20 22:39 4828